Dan Spiegelman has over 25 years of Biotech finance experience. Dan was most recently CFO and EVP of BioMarin Pharmaceutical Inc (2012-2020), a company focused on developing, manufacturing and commercializing treatments for rare genetic disorders. Dan oversaw growth from $500M in revenues to $2.0B in revenues with sales in 70 countries and from $4b market cap to $20b. Prior to BioMarin, Dan served as CFO and SVP of CV Therapeutics for 11 years through its sale in 2009 to Gilead for $1.4 Billion, and before that was Treasurer at Genentech. Dan currently provides consulting and board services to various life sciences companies. He currently serves on the Board of Directors of Myriad Genetics (Nasdaq:MYGN), Spruce Biosciences (Nasdaq:SPRB), Jiya Acquisition Corp (Nasdaq:JYAC), Opthea Limited (Nasdaq: OPT) and several private biotechnology companies. Dan received his Master’s in Business Administration from the Stanford Graduate School of Business and a Bachelor’s in Economics from Stanford University.